Session » Sjögren’s Syndrome Poster

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1251

Assessing the Construct Validity of the Novel OMERACT Ultrasound Scoring System for Salivary Glands Target Lesions by Comparison with MRI in Patients with Sjögren’s Syndrome – An OMERACT Ultrasound Working Group Exercise

9:00AM-11:00AM: Abstract Number: 1244

Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1250

Early Sjögren Antibodies: Potential Biomarker for Abnormal Minor Labial Salivary Gland Biopsy in Juvenile Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1247

Features of Childhood Sjogren’s Syndrome: A Literature Review Based Cohort

9:00AM-11:00AM: Abstract Number: 1254

Lack of Efficacy of Early Treatment with Hydroxychloroquine in a Group of Hispanics with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1256

Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production

9:00AM-11:00AM: Abstract Number: 1248

Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort

9:00AM-11:00AM: Abstract Number: 1253

Re-evaluation of the Extent of Lymphocytic Infiltration May Improve the Diagnostic Accuracy of Lip Biopsy in Primary Sjögren’s Syndrome (pSS)

9:00AM-11:00AM: Abstract Number: 1243

Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression

9:00AM-11:00AM: Abstract Number: 1246

Sjogren’s Syndrome and Its Risk of Cervical Lesions

9:00AM-11:00AM: Abstract Number: 1255

Sjӧgren’s Syndrome Minor Salivary Gland Mesenchymal Stromal Cells Derived Deploy Intact Immune Plasticity and Display Myofibroblast-Like Properties

9:00AM-11:00AM: Abstract Number: 1245

Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1249

The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies

9:00AM-11:00AM: Abstract Number: 1242

Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study

9:00AM-11:00AM: Abstract Number: 1252

Ultrasound-guided Parotid Gland Biopsy in Cadavers Performed by Rheumatologists – an OMERACT Ultrasound Working Group Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].